JAZZ

#794
Jazz Pharmaceuticals, Inc.
199.5850 USD
+2.19%
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
199.3200
199.6500
Intervallo Annuale
128.8000
200.2400
Variazione giornaliera
+2.19%
Variazione Mensile
+11.05%
Variazione di 6 mesi
+42.56%
Variazione Annuale
+42.56%
Chiusura Precedente
195.3100
Apertura
199.5000
Bid
Ask
Minimo
199.3200
High
199.6500
Volume
97
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche
Trimestrale Annuale
  • Market Capitalization 12.2865 B
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Technology
Ricavi totali
Utile netto
Utile base per azione (EPS base)
Debito totale
Liquidità libera
Disponibilità liquide e mezzi equivalenti
Rapporto prezzo/utili
-29.11
Rapporto prezzo/fatturato
2.43

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

Notizie